The transformative success of antibodies targeting the PD-1 (programmed death 1)/B7-H1
(B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However …

The discovery of immune checkpoint inhibitors (ICIs) has now been universally
acknowledged as a significant breakthrough in tumor therapy after the targeted treatment of …

Following their exit from the thymus, T cells are endowed with potent effector functions but
must spare host tissue from harm. The fate of these cells is dictated by a series of …

V-domain Ig suppressor of T cell activation (VISTA) is a B7 family member that maintains T
cell and myeloid quiescence and is a promising target for combination cancer …

Over the past two decades, immunotherapies have increasingly been considered as first-
line treatments for most cancers. One such treatment is immune checkpoint blockade (ICB) …

Simple Summary Although the incorporation of immune checkpoint inhibitors (ICIs) in
melanoma treatment has significantly improved prognosis for patients with advanced …

V-domain immunoglobulin suppressor of T cell activation (VISTA) is a novel negative
checkpoint receptor (NCR) primarily involved in maintaining immune tolerance. It has a role …

Cancer immunotherapy, exemplified by the remarkable clinical benefits of the immune
checkpoint blockade and chimeric antigen receptor T-cell therapy, is revolutionizing cancer …

Simple Summary Spine metastases are a common life-threatening complication of
advanced-stage malignancies and often result in poor prognosis. Symptomatic spine …

In the tumor microenvironment, T cells, B cells, and many other cells play important and
distinct roles in anti‐tumor immunotherapy. Although the immune checkpoint blockade and …